We investigated the effects of replication-defective herpes simplex virus (HSV) vector expression of interleukin-4 (IL-4) on bladder overactivity and nociception. HSV vector expressing murine interleukin-4 (S4IL4) or the control vector expressing b-galactosidase (SHZ) were injected to the rat bladder wall. At 1 week after viral injection, in cystometry performed under urethane anesthesia, the S4IL4-treated group did not show the intercontraction intervals reduction during intravesical administration of 10 nM resiniferatoxin (RTx). At 2 weeks after viral injection, behavioral studies were performed on vectorinjected animals in an awakened state. Freezing behavior induced by 3 mM RTx, administered for 1 min into the bladder, was significantly suppressed in the S4IL4 group compared with the SHZ group. Murine IL-4 levels examined by ELISA were significantly increased in bladder and bladder afferent dorsal root ganglia at 2 weeks after viral injection. The expression of IL-1b and IL-2 and bladder inflammatory responses were significantly suppressed in the RTx-irritated bladder of S4IL4-injected rats. These results indicate that HSV vector-mediated interleukin-4 expression in the bladder and bladder afferent pathways reduces the inflammatory response, bladder overactivity and nociceptive behavior induced by bladder irritation in the rat model. Therefore, IL-4 gene therapy could be a new strategy for treating urinary frequency and/or bladder pain.
INTRODUCTION
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a serious disease characterized by increased bladder pain and urinary frequency that is often difficult to treat due to the variation and severity in patient symptoms. Although the etiology of IC/PBS is not fully understood, bladder inflammation associated with production of inflammatory cytokines has been proposed as a potential cause of pathogenesis of the disease. 1, 2 In previous studies, cytokines and chemokines, such as interleukin-2 (IL-2), IL-6, IL-8 and tumor necrosis factor-alpha (TNFa), were significantly increased in IC/PBS patients' bladder tissue and urine than in controls, suggesting that these cytokines might represent specific markers of IC/PBS. 2 --4 In contrast, IL-4 is a prototypical antiinflammatory cytokine, which is known to inhibit secretion of inflammatory cytokines, such as IL-1b, TNFa and IL-6.
5 --7 IC/PBS patients have displayed lower levels of IL-4 8 that increased following treatment with a drug (IPD-1151T) that altered the IC/PBS phenotype and symptoms in these IC/PBS patients, suggesting that IL-4 may provide a desired anti-inflammatory effect that can alter the overall cytokine profile and subsequent recruitment of T cells and mast cells. 9 However, because of the pleiotropic effects of IL-4 on the whole body immune system and the relatively short half-life of the peptide, systemic IL-4 administration would not be suitable for treatment of inflammatory pain conditions in humans, suggesting an alternative strategy for delivering IL-4 as a therapeutic is necessary.
Previous studies showed the efficacy of gene delivery using replication-deficient herpes simplex virus (HSV) vectors, which encode therapeutic genes such as preproenkephalin or glutamic acid decarboxylase (GABA synthesis enzyme), to target organs as an efficient way to administer short half-life peptides. 10 --14 It has also been demonstrated that HSV vectors injected to the bladder wall can transduce to L6-S1 DRG via afferent nerve termini, which innervate the bladder, and express reporter or therapeutic gene products in the bladder and dorsal root ganglia (DRG) for up to several weeks in rats. 15, 16 We have also reported that rats treated with HSV vectors expressing preproenkephalin showed reductions in bladder overactivity and nociceptive behavior induced by capsaicin. 15 However, to date, the effect of anti-inflammatory therapy using HSV vectors expressing IL-4 has not been studied in bladder pain and overactivity animal models, although a previous study showed that HSV-based IL-4 gene therapy was effective in a rat model of neuropathic pain.
14 Therefore, we examined the effects of localized and targeted gene therapy using replication-deficient HSV vectors expressing murine IL-4 on bladder overactivity and nociceptive behavior induced by intravesical application of resiniferatoxin (RTx), a potent analog of capsaicin, in rats.
RESULTS

Histochemistry of HSV vector-mediated transgene expression
At 1 week after injection of the HSV virus vector SHZ expressing b-galactosidase (HSV-lacZ) (Figure 1 ), we observed histochemical reactivity for b-galactosidase (lacZ) in both the bladder (data not shown) and L6 DRG, which contain bladder afferent neurons ( Figure 2) . In DRG sections, small and medium size cell bodies of afferent neurons stained positively for lacZ expression as we similarly found in our previous studies using the same SHZ vector. 15, 17, 18 We also previously demonstrated that lacZ expression is observed mainly in the muscle layer of the bladder after bladder wall inoculation of the same SHZ vector. 15, 17, 18 These results indicate that HSV vectors can be transported to bladder afferent pathways after their bladder wall inoculation.
Quantitation of HSV vector-mediated IL-4 expression by ELISA HSV vector-mediated IL-4 upregulation in the bladder and L6 DRG were evaluated using ELISA. At 2 weeks after viral vector injection, elevated expression of murine IL-4 protein was detected in L6 DRG and the bladder of rats injected with the HSV vector S4IL4 expressing IL-4 (HSV-IL4) ( Figure 1 ) by ELISA ( Figure 3 ). In the bladder, a significant difference was detected between the SHZ (n ¼ 4) and S4IL4 (n ¼ 4) animal groups (0.01 ± 0.01 pg mgTP À1 vs 5.62 ± 1.64 pg mgTP
À1
). In L6 DRG of S4IL4-injected rats, there was 13.27±3.76 pg mgTP À1 of murine IL-4, whereas no murine IL-4 was detected in L6 DRG of SHZ-injected rats. These results indicate that the IL-4 protein levels were increased after IL-4-expressing HSV vector inoculation in the bladder.
Cystometric assessment of bladder function Figure 4 shows representative traces of intravesical pressure during cystometry of the SHZ and S4IL4 animal groups (1 week after viral injection). There were no significant differences in ICI (intercontraction interval) between the S4IL4 (n ¼ 9) and SHZ groups (n ¼ 9) during 2 h of saline infusion (P ¼ 0.34), indicating that S4IL4 did not affect normal bladder activity. However, expression of IL-4 from the S4IL4-treated rats suppressed bladder overactivity induced by nociceptive stimuli in the bladder. After RTx administration (Figure 5 ), the SHZ-injected control vector group showed a significant reduction in the ICI (Po0.05), whereas the ICI of S4IL4-treated rats was not significantly altered (P ¼ 0.42). These results indicate that IL-4 gene transfer treatment can suppress bladder overactivity induced by RTx-induced bladder irritation without affecting baseline bladder activity.
Nociceptive behavior in response to pain induced by RTx We evaluated the effects of S4IL4 treatment 2 weeks after the bladder injection to examine whether the effects of IL4 gene transfer last more than 1 week, as consistent with HSV vectormediated transgene expression that lasted up to 4 weeks. 15, 18 We had previously established a methodology for examining the behavior of rats in response to painful stimuli, such as capsaicin or RTx when administered to the bladder thereby affecting the bladder afferents, by measuring the number and intervals of time spent on licking or freezing behavior. 15, 19 Licking behavior after bladder RTx stimulation (Figure 6a HSV vector-mediated expression of IL-4 reduces expression of IL-1b and IL2 SHZ vector-treated rats (n ¼ 4) showed significantly increased expression of IL-1b (84.42 ± 9.62 pg mgTP À1 ) (Po0.05) after intravesical RTx injection compared with RTx-injected S4IL4 rats (n ¼ 4) and saline-injected sham rats (n ¼ 4) (42.12 ± 7.98 and 36.62 ± 3.00 pg mgTP À1 , respectively) ( Figure 7 ). There was no significant difference in IL-1b levels between S4IL4 vector-injected and sham rats, indicating that IL-4 gene delivery almost completely suppressed the RTx-induced IL-1b increase in the bladder ( Figure 7 ). In addition, multiplex analyses using an automated immunoassay analyzer, Luminex 200 (Bio-Rad, Hercules, CA, USA), also revealed that the increased expression of IL-1b and IL-2 that was seen after intravesical RTx administration (3 mM, 0.3 ml for 1 min) in STZ-injected rats (n ¼ 6) were prevented in S4IL4-injecetd rats (n ¼ 6) (Table 1) . However, IL-6 or TNFa levels were not altered after intravesical RTx administration in either SHZ-or S4IL4-injecetd rats ( Table 1 ), indicating that increased expression of IL-6 or TNFa is not induced in this animal model of RTx-induced bladder irritation.
Assessment of inflammatory responses in the bladder
The effects of HSV vector-mediated IL-4 expression on bladder inflammatory responses were evaluated by histological analysis of hematoxylin and eosin-stained bladder specimens and myeloperoxidase (MPO) assay that can measure tissue neutrophil activity ( Figure 8 ). There were histological changes such as submucosal edema evidenced by an increase in the mucosal layer width after intravesical RTx administration (3 mM, 0.3 ml for 1 min) in SHZ-treated rats; however, submucosal edema was less in S4IL4-treated rats with RTx-induced bladder irritation (Figure 8a and b) . In addition, an increase in MPO activity, which was seen after intravesical RTx administration (3 mM, 0.3 ml for 1 min) compared with vehicle treatment in SHZ-injected rats (n ¼ 6), was prevented in S4IL4-treated rats with RTx-induced bladder irritation (Figure 8c ). These results suggest that increased IL-4 expression in S4IL4 rats can suppress bladder inflammatory responses induced by bladder irritation. (b) Freezing behavior, which is mainly dependent on pelvic nerve activation, was suppressed by S4IL4 ((n ¼ 7 in SHZ, n ¼ 8 in S4IL4) n.s., not significant, *Po0.05).
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DISCUSSION
We had previously employed HSV vectors expressing products such as enkephalin 15 and GAD67 16 as means of reducing pain signaling as measured by changes in behavior and/or bladder activity when the vectors were injected into the bladder wall of rats. These earlier studies dealt with products that directly altered the afferents without addressing the inflammatory component of the nociceptive process. Other studies using an HSV vector (S4IL4) expressing murine IL-4 showed that this product, when expressed in DRG afferents following vector administration to the plantar foot surface, 14 enabled a reduction in nociceptive behaviors after painful insult. Our current study was initiated to examine whether the same S4IL4 vector when administered into the bladder wall of the rat would result in IL-4 expression that was capable of reducing the inflammatory component of the pain response in bladder afferent pathways.
The results of this study indicate that: (i) HSV vectors injected into the bladder wall are transported into L6 DRG neurons via afferent nerve fibers; (ii) significant increases of murine IL-4 were detected in the bladder and L6 DRG from S4IL4 vector-injected rats; (iii) in S4IL4-treated rats, the ICI was not reduced during RTx intravesical administration, which induced bladder overactivity in SHZ-treated control rats; (iv) S4IL4-injected rats showed a reduction in freezing behavior; and (v) increased expression of IL-1b and IL-2 as well as bladder inflammatory responses, such as submucosal edema and enhanced MPO activity, elicited by RTx-induced bladder irritation was reduced in S4IL4-treated rats.
In this study, although freezing behavior was significantly reduced, there was no difference in licking behavior between SHZ-and S4IL4-treated rats. This is probably due to the fact that licking behavior is induced by stimulation of urethral afferents in the pudendal nerve rather than bladder afferents, because previous studies including ours have demonstrated that pudendal nerve transection significantly reduces licking behavior, but not freezing behavior, induced by intravesical application of capsaicin 20 or RTx. 19 We have also shown that administration of HSV vectors expressing proenkephalin into the bladder wall suppresses freezing behavior, but not licking behavior, induced by intravesical application of capsaicin. Thus, these results provide evidence that the effects of IL-4 gene transfer after S4IL4 bladder injection are limited to bladder afferent pathways, which are carried through the pelvic nerves, but not the pudendal nerves, and that neither the vector nor the transgene is having pleiotropic effects on other non-target sites.
The antinociceptive effects of HSV-IL4 treatment were found up to 2 weeks after injection in this study. In a previous study using a rat model of neuropathic pain, the antinociceptive effect of HSV-IL4 lasted up to 4 weeks post injection, and reinoculation of HSV-IL4 re-instated the antinociceptive effect.
14 Another study using HSV vectors expressing proenkephalin also showed the presence of HSV-mediated protein expression for 4 weeks in the bladder and L6 DRG following bladder wall injection. 15 Thus, HSVbased gene delivery to bladder afferents could avoid frequent administration of short half-life peptides in a target organ, and the lack of off-target activity suggests that this type of delivery would avoid systemic side effects that have also been observed using direct delivery of the therapeutic protein(s). 21 HSV vectors expressing IL-4 have been employed in a variety of applications where the activity of IL-4 has been shown to have a Figure 7 . Quantification of IL-1b levels by ELISA in S4IL4-injected vs control vector-treated rats after bladder irritation with RTx. SHZ-treated rats showed significantly increased IL-1b expression compared with S4IL4-treated rats with RTx stimulation or HSVuninjected sham rats without RTx. S4IL4 rats showed similar levels of IL-1b to those from RTx-untreated sham rats ((n ¼ 4 each) n.s., not significant, *Po0.05). Table 1 . Multiplex analyses of cytokines in bladder tissues 
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role in altering the immune response within the host. The S4IL4 vector was able to reduce both mucosal and systemic immunity, in response to challenge with wild-type HSV, and block zosteriform spread. 22 Other studies have been performed using a similar vector to the S4IL4 recombinant where HSV vector-mediated expression of IL-4 led to a reduction in the host immune response to wild-type virus infection, in this instance, during infection of the eye that resulted in failure of the host to clear the wild-type virusinfected cells. 22--24 HSV vectors expressing IL-4 have also been used as a therapeutic to reduce autoimmune disease in the central nervous system, such as experimental autoimmune encephalitis 25 --29 and also Alzheimer's disease in animal models. 30 Taken together, these studies support the use of HSV vector-mediated IL-4 expression to reduce or augment the host inflammatory response, and when these results are taken into account along with the earlier study using S4IL4 injection into rodent footpad, 14 they set up the basis for our current study examining IL-4 effects of bladder pain induced by RTx administration.
Inflammatory cytokines or chemokines have been reported to be involved in the development of inflammatory pain. 31 --33 It has been reported that the release of cytokines or chemokines has an important role in the neuropathic pain 33 --36 and that, in the rodent models of neuropathic pain, antagonists of proinflammatory cytokine such as IL-1b reportedly reduced allodynia. 37 Meanwhile, IL-4 is recognized as one of the anti-inflammatory cytokines, which suppresses the expression of IL-1b mRNA and IL-1b protein. 38 Another study also indicated that IL-4 suppresses TNFa, IL-1 and PGE 2 (prostaglandin E2) in human monocytes in vitro.
39 IL-4 injection to the plantar inhibited the inflammatory hyperalgesia caused by carrageenin, bradykinin and TNFa. 40 IL-4 injection into the peritoneal cavity also suppressed writhing behavior induced by zymosan or acetic acid in mice, and knee joint incapacitation induced by zymosan in rats. 41 The present study also showed that HSV vector-mediated IL-4 gene therapy suppressed increased expression of IL-1b and IL-2 as well as bladder inflammatory responses, such as submucosal edema and enhanced MPO activity, elicited by RTx-mediated bladder irritation. Overall, the anti-inflammatory cytokine IL-4 seems to effectively suppress inflammation and the nociceptive responses associated with that inflammation.
It has been also demonstrated that proinflammatory cytokines, such as IL-2, IL-6, IL-8 and TNFa, are increased in the bladder and/or urine in IC/PBS patients. 1 --4 Thus, although the etiology of IC/PBS seems to be multifactorial, neurogenic inflammation associated with cytokine/chemokine production could have an important role in the pathophysiological basis of the disease. In this study, HSV vector-mediated gene delivery of IL-4 into the bladder and bladder afferent pathways reduced the elevated levels of IL-1b and IL-2 in the bladder and suppressed bladder pain behavior as well as bladder overactivity elicited by RTx-induced chemical bladder irritation. It has also been reported that IL-4 has an anti-inflammatory effect to inhibit secretion of inflammatory cytokines including TNFa and IL-6, 5 --7 which are reportedly increased in the bladder of IC/PBS patients.
2 --4 Thus, HSV-based IL-4 gene therapy could be an attractive modality for the treatment of IC/PBS by suppressing the inflammatory component of the disease process, although the effects of HSV-based IL-4 gene therapy on inflammatory cytokines, such as TNFa and IL-6, should be clarified in future studies.
MATERIALS AND METHODS Animals
Female Sprague --Dawley rats weighing 230 --260 g were purchased from Hilltop Animal Care (Pittsburgh, PA, USA) and used according to the experimental protocol approved by the University of Pittsburgh Institutional Animal Care and Use Committee.
Viral vectors
HSV vector S4IL4 expressing IL-4 (HSV-IL4) was produced as previously described 22 using Cre-lox recombination of a plasmid that contains ICP4 promoter driving the murine IL-4 gene in addition to the HCMV IE promoter-b-galactosidase expression cassette and a lox combination site into the thymidine kinase locus of d120, 42 which is a replication-defective KOS strain HSV mutant, containing a deletion of both copies of the immediate-early ICP4 gene. As an isogenic control vector, we employed the SHZ (HSV-lacZ) virus that has the HCMV IE promoter-b-galactosidase expression cassette recombined into thymidine kinase locus of d120 by similar techniques (Figure 1 ).
In vivo viral infection
Under pentobarbital anesthesia (30 mg kg À1 ), with lower abdominal incision, the vectors were injected to the bladder wall using a 30-gauge 10 ml Hamilton syringe (Hamilton, Reno, NV, USA). A total of 20 ml of viral suspension of S4IL4 or SHZ (8 Â 10 4 PFU) was injected to four different sites of the bladder wall (5 ml at each site). After viral injection, rats were allowed to recover from anesthesia and then they were housed in an approved Biosafety level 2 animal facility.
Histology
At 1 week after bladder injection of the SHZ control vector, rats were euthanized to harvest the bladder and L6 DRG for the detection of lacZ gene expression by X-gal staining. Cryostat sections (10 mm) of tissues were mounted on gelatin-coated slides and fixed for 1 min in 1.5% glutaraldehyde (Sigma-Aldrich, St Louis, MO, USA). Then, slides were rinsed twice in phosphate-buffered saline, and incubated overnight at 37 1C in the b-galactosidase substrate solution . In addition, the bladders from SHZ-or S4IL4-treated rats were removed 6 h after intravesical RTx administration (3 mM, 0.3 ml for 1 min), then fixed in an ice-cold 4% paraformaldehyde solution containing 0.21% picric acid in 0.1 M PB (phosphate buffer) for 48 h, and soaked overnight at 4 1C in 0.1 M PB containing increasing concentrations of sucrose (10 --30%). The frozen tissues were cut at 10 mm thickness (transverse sections) and stained with hematoxylin and eosin.
Expression of IL-4
At 2 weeks after HSV vector injection, rats were euthanized to harvest the bladder and L6 DRG. Tissues were frozen on dry ice and stored at À80 1C. The tissue was homogenized and the protein was extracted with RIPA buffer (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The amount of murine IL-4 was determined by murine IL-4 ELISA kit according to the manufacturer's instruction (R&D Systems, Minneapolis, MN, USA). All samples were run in duplicates. The levels of IL-4 were normalized to protein concentration, which was measured using a protein assay kit (Pierce, Rockford, IL, USA), and the results were expressed as picogram IL-4 per milligram of total protein (pg mgTP À1 ).
Cystometry
At 1 week after viral vector injection, cystometry was performed under urethane anesthesia (1.2 g kg À1 , subcutaneously). With a lower abdominal incision, a PE-50 tube (Clay Adams Division of Becton Dickinson, Parsippany, NJ, USA) was inserted to the bladder through the bladder dome. An intravesical catheter was then connected to a pressure transducer and to an infusion pump through a 3-way stopcock. Data was collected and analyzed with a software package (PowerLab, ADInstruments, Castle Hill, NSW, Australia). After a baseline recording was established with saline infusion at 0.04 ml min À1 , 10nM RTx was continuously administered at 0.04 ml min À1 to the bladder to induce bladder overactivity in both S4IL4-and SHZ-injected rats (n ¼ 9 each).
Evaluation of nociceptive behavior
The methods for evaluation of nociceptive behavior in rats followed those described in our previous study. 19 Intravesical administration of RTx induces nociceptive behavior such as licking (lower abdominal licking) and Effect of HSV vector-mediated IL-4 gene therapy T Oguchi et al freezing (immobility with pointing their nose toward the lower abdomen without licking). At 2 weeks after S4IL4 (n ¼ 8) or SHZ (n ¼ 7) vector injection, rats were placed in metabolic cages for 2 h for acclimation. After acclimation, 3 mM RTx (0.3 ml) was administered into the bladder through a temporary indwelling transurethral catheter and retained in the bladder for 1 min using a Bollman-type restraining device (KN-326, Natsume Seisakusho, Tokyo, Japan) to induce bladder pain behavior in a conscious condition. Thereafter, the transurethral catheter was removed, and rats were placed back in metabolic cages for evaluation. Nociceptive behaviors, such as licking and freezing, were observed and scored by blinded observers for 15-min periods that were divided into 5-s intervals. When licking or freezing occurs during each 5-s interval, it was scored as one positive event. Thus, the maximal nociceptive score could be 180 during the 15-min observation period.
Expression of IL-1 b in bladder after RTx stimulation At 2 weeks after S4IL4 or SHZ vector injection (n ¼ 4 each), rats were administrated 3 mM RTx (0.3 ml, 1 min) to the bladder through a transurethral catheter to induce bladder irritation. Sham rats (n ¼ 4) without viral injection were administrated 0.3 ml of saline to the bladder through the transurethral catheter. Rats were eutahnized 6 h after RTx or saline administration, and the bladder was harvested to examine the expression of IL-1b using an ELISA kit (R&D Systems). Thereafter, multiplex analyses using an automated immunoassay analyzer, Luminex 200 (BioRad) with a MILLIPLEX MAP Rat Cytokine/Chemokine Panel (Millipore, Billerica, MA, USA) were also used to assay TNFa, IL-1b, IL-2 and IL-6 levels in bladder tissues of S4IL4-and SHZ-injected rats with intravesical RTx administration (3 mM, 0.3 ml for 1 min) (n ¼ 6 each). Bladder tissues were homogenized using RIPA lysis buffer, and homogenate was centrifuged at 10 000 r.p.m. for 10 min and the supernatants were stored at À80 1C until measured. The levels of cytokines were normalized to protein concentration and expressed as pg mgTP À1 .
MPO assay
MPO concentration in bladder tissues of S4IL4-and SHZ-injected rats 6 h after intravesical RTx administration (3 mM, 0.3 ml for 1 min) (n ¼ 6 each) was measured using a specific ELISA kit (Hycult Biotech, Plymouth Meeting, PA, USA). Protein concentration was determined using a Bio-Rad kit with bovine serum albumin as the standard. The MPO concentrations were standardized to tissue protein levels and expressed in ng mgTP À1 .
Statistical analysis
Data are shown as the mean± s.e. Statistical comparisons were made with the Wilcoxon signed rank test for paired data and Mann --Whitney U-test for unpaired data, as applicable, with Po0.05 considered statistically significant.
